CEVEC Pharmaceuticals GmbH
Booth number 4507-09CEVEC is a leading provider of high-performance cell technologies for the manufacturing of viral vectors for gene therapy and vaccine applications.
About us
As a leading provider of high-performance cell technology for the manufacturing of advanced bio-therapeutics, CEVEC’s product portfolio comprises various platform technologies for gene therapy vectors and vector vaccines. ELEVECTA® is the technology of choice for AAV manufacturing. For RCA-free Adenoviral vectors, the CAP® Ad technology is the perfect fit.
Address
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen-Str. 60
51105 Cologne
Germany
Phone: +49 221 46020800
Internet: www.cevec.com
Products and Services
With the ELEVECTA® Technology, CEVEC offers a unique solution for large-scale production of AAV vectors using helper virus-free producer cell lines with all necessary components stably integrated into the cell. The technology does not require any expensive transfection reagents or cGMP plasmids.
CEVEC’s CAP® Ad Technology based on proprietary human suspension cells is the production platform of choice for RCA-free adenoviral vectors. The platform design allows for easy scale-up and opens the way for various applications, from gene therapy to vaccine production.
ELEVECTA®
With the ELEVECTA® Technology, CEVEC offers a unique solution for large-scale production of AAV vectors using helper virus-free producer cell lines with all necessary components stably integrated into the cell.
Click here if you notice an image that violates copyright or privacy rights.